Oncology Reviews最新文献_第10页

Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy 癌症基因组学与免疫的结合：胰腺癌免疫治疗的研究现状和未来方向

IF 3.6

Oncology Reviews Pub Date : 2019-07-22 DOI: 10.4081/oncol.2019.430

Jacob S. Bowers, Stefanie R. Bailey, M. Rubinstein, C. Paulos, E. Camp

{"title":"Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy","authors":"Jacob S. Bowers, Stefanie R. Bailey, M. Rubinstein, C. Paulos, E. Camp","doi":"10.4081/oncol.2019.430","DOIUrl":"https://doi.org/10.4081/oncol.2019.430","url":null,"abstract":"Pancreatic adenocarcinoma (PDAC) remains a formidable disease that needs improved therapeutic strategies. Even though immunotherapy has revolutionized treatment for various solid tumor types, it remains largely ineffective in treating individuals with PDAC. This review describes how the application of genome-wide analysis is revitalizing the field of PDAC immunotherapy. Major themes include new insights into the body’s immune response to the cancer, and key immunosuppressive elements that blunt that antitumor immunity. In particular, new evidence indicates that T cell-based antitumor immunity against PDAC is more common, and more easily generated, than previously thought. However, equally common are an array of cellular and molecular defenses employed by the tumor against those T cells. These discoveries have changed how current immunotherapies are deployed and have directed development of novel strategies to better treat this disease. Thus, the impact of genomic analysis has been two-fold: both in demonstrating the heterogeneity of immune targets and defenses in this disease, as well as providing a powerful tool for designing and identifying personalized therapies that exploit each tumor’s unique phenotype. Such personalized treatment combinations may be the key to developing successful immunotherapies for pancreatic adenocarcinoma.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.430","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46867961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Prognostic significance of mutated genes in megakaryocytic disorders 突变基因在巨核细胞疾病中的预后意义

IF 3.6

Oncology Reviews Pub Date : 2019-07-22 DOI: 10.4081/oncol.2019.408

A. Asnafi, M. Mohammadi, Hadi Rezaeeyan, Nader Davari, N. Saki

{"title":"Prognostic significance of mutated genes in megakaryocytic disorders","authors":"A. Asnafi, M. Mohammadi, Hadi Rezaeeyan, Nader Davari, N. Saki","doi":"10.4081/oncol.2019.408","DOIUrl":"https://doi.org/10.4081/oncol.2019.408","url":null,"abstract":"Megakaryopoiesis is a process during which platelets that play a major role in hemostasis are produced due to differentiation and maturation of megakaryocytic precursors. Several genes, including oncogenes and tumor suppressor genes, play a role in the regulation of this process. This study was conducted to investigate the oncogenes and tumor suppressor genes as well as their mutations during the megakaryopoiesis process, which can lead to megakaryocytic disorders. Relevant literature was identified by a PubMed search (1998-2019) of English language papers using the terms ‘Megakaryopoiesis’, ‘Mutation’, ‘oncogenes’, and ‘Tumor Suppressor’. According to investigations, several mutations occur in the genes implicated in megakaryopoiesis, which abnormally induce or inhibit megakaryocyte production, differentiation, and maturation, leading to platelet disorders. GATA-1 is one of the important genes in megakaryopoiesis and its mutations can be considered among the factors involved in the incidence of these disorders. Considering the essential role of these genes (such as GATA- 1) in megakaryopoiesis and the involvement of their mutations in platelet disorders, study and examination of these changes can be a positive step in the diagnosis and prognosis of these diseases.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.408","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45253034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

CDK4/6 inhibitors in advanced breast cancer, what is beyond? CDK4/6抑制剂在晚期乳腺癌中的作用?

IF 3.6

Oncology Reviews Pub Date : 2019-07-22 DOI: 10.4081/oncol.2019.416

Amrallah A. Mohammed, Hanaa Rashied, F. M. Elsayed

引用次数: 8

Thrombocytopenia in solid tumors: Prognostic significance. 实体瘤中的血小板减少症：预后意义。

IF 3.1

Oncology Reviews Pub Date : 2019-05-14 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.413

Majid Ghanavat, Mina Ebrahimi, Hassan Rafieemehr, Mahmood Maniati, Masumeh Maleki Behzad, Saeid Shahrabi

引用次数: 0

Prognostic significance of aberrant CD5 expression in B-cell leukemia. CD5异常表达在b细胞白血病中的预后意义。

IF 3.6

Oncology Reviews Pub Date : 2019-04-18 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.400

Kaveh Jaseb, Daryush Purrahman, Saeid Shahrabi, Majid Ghanavat, Hadi Rezaeean, Najmaldin Saki

{"title":"Prognostic significance of aberrant CD5 expression in B-cell leukemia.","authors":"Kaveh Jaseb, Daryush Purrahman, Saeid Shahrabi, Majid Ghanavat, Hadi Rezaeean, Najmaldin Saki","doi":"10.4081/oncol.2019.400","DOIUrl":"https://doi.org/10.4081/oncol.2019.400","url":null,"abstract":"Aberrant expression of CD5 (as a T-cell marker) is seen in some leukemia and lymphoma of B lineage origin. Given that the signaling resulting from the expression of this marker plays an essential role in the development of leukemia and lymphoma, evaluating the expression of this marker is of paramount importance. Therefore, our goal in this study was to investigate the prognostic importance of CD5 expression in B-cell leukemia and lymphoma. We evaluate CD5 expression in normal and leukemic B-cells by identifying relevant literature through a PubMed search (1998-2018) of English language papers using the terms: 'CD5,' 'B-cell,' 'Leukemia,' and 'Lymphoma.' We are doing this thorough comparison of results from CD5 positive and negative cases to make a correct decision about prognostic importance of CD5 expression in these malignancies. In a number of B-cell malignancies, CD5 is expressed in varying degrees. Due to the different origins and characteristics of these malignancies, the results of CD5 expression evaluations are heterogeneous and impossible to generalize. However, CD5 expression is sometimes associated with clinicopathologic findings, more invasive clinical course, and even resistance to treatment (specifically in DLBCL) among CD5- positive patients, which appears to be a function of CD5 signaling and its downstream factors such as STAT3. Depending on the type of malignancy, CD5 expression is associated with good or bad prognosis, which can be used as an auxiliary prognostic factor to assess the clinical course of B-cell malignancies. Moreover, the difference in expression levels of CD5 in a variety of B-cell malignancies allows for differential diagnosis of these malignancies, which can be helpful when diagnosis is difficult.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"400"},"PeriodicalIF":3.6,"publicationDate":"2019-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.400","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37204652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Prospects for repurposing CNS drugs for cancer treatment. 中枢神经系统药物用于癌症治疗的前景。

IF 3.6

Oncology Reviews Pub Date : 2019-04-17 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.411

Mohamed Abdelaleem, Hossam Ezzat, Muhammed Osama, Adel Megahed, Waleed Alaa, Ahmed Gaber, Ayman Shafei, Alaa Refaat

引用次数: 22

Adherence to oral pharmacological treatment in cancer patients: Systematic review. 癌症患者口服药物治疗的依从性:系统评价。

IF 3.6

Oncology Reviews Pub Date : 2019-04-16 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.402

Melissa Perdomo Claros, Claudia Viviana Marín Messa, Herney Andrés García-Perdomo

{"title":"Adherence to oral pharmacological treatment in cancer patients: Systematic review.","authors":"Melissa Perdomo Claros, Claudia Viviana Marín Messa, Herney Andrés García-Perdomo","doi":"10.4081/oncol.2019.402","DOIUrl":"https://doi.org/10.4081/oncol.2019.402","url":null,"abstract":"The objective was to identify the best-validated scale for assessing oral pharmacological adherence in oncology patients. A bibliographic search was performed in MEDLINE via Ovid, EMBASE, CENTRAL and LILACS. We included all studies in which a validation of adherence scales to oral pharmacological treatment was performed in oncology patients older than 18 years without gender distinction. We excluded studies that included newly diagnosed patients. No statistical analysis was performed due to the nature of the study. A total of 4609 studies were found. After screening, six studies were selected for qualitative analysis. In the analysis of the six included studies, a total of 855 patients older than 18 years with oncological diagnoses were found. Two of the studies, Bagcivan et al. and Amorim et al., used scales that show acceptable validity and reliability to adequately measure adherence to pharmacological treatment in each of the patients. In this way, the quality of patient care and success in pharmacological treatments can be guaranteed. According to the results obtained in the evaluation of biases and analysis of psychometric properties, the best-validated scales are as follows: Adherence Determinants Questionnaire (ADQ) (Brazilian version) and the Oral Chemotherapy Adherence Scale (OCAS). These are valid, reliable and useful scales that can be adapted to any cultural context.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"402"},"PeriodicalIF":3.6,"publicationDate":"2019-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.402","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37204653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

A comprehensive overview of mitochondrial DNA 4977-bp deletion in cancer studies. 线粒体DNA 4977-bp缺失在癌症研究中的全面概述。

IF 3.6

Oncology Reviews Pub Date : 2019-04-16 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.409

Abdul Aziz Mohamed Yusoff, Wan Salihah Wan Abdullah, Siti Zulaikha Nashwa Mohd Khair, Siti Muslihah Abd Radzak

引用次数: 32

Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility. 骨髓增生异常综合征的复杂核型:诊断程序和预后易感性。

IF 3.6

Oncology Reviews Pub Date : 2019-02-04 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.389

Mohammad Shahjahani, Elham Homaei Hadad, Shirin Azizidoost, Kowsar Chenani Nezhad, Saeid Shahrabi

{"title":"Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility.","authors":"Mohammad Shahjahani, Elham Homaei Hadad, Shirin Azizidoost, Kowsar Chenani Nezhad, Saeid Shahrabi","doi":"10.4081/oncol.2019.389","DOIUrl":"https://doi.org/10.4081/oncol.2019.389","url":null,"abstract":"Complex karyotype (CK) is a poor prognosis factor in hematological malignancies. Studies have shown that the presence of CK in myelodysplastic syndrome (MDS) can be associated with MDS progression to acute myeloid leukemia. The goal of this review was to examine the relationship between different types of CK with MDS, as well as its possible role in the deterioration and progression of MDS to leukemia. The content used in this paper has been obtained by a PubMed and Google Scholar search of English language papers (1975-2018) using the terms complex karyotype and myelodysplastic syndromes. A single independent abnormality can be associated with a good prognosis. However, the coexistence of a series of abnormalities can lead to CK, which is associated with the deterioration of MDS and its progression to leukemia. Therefore, CK may be referred to as a prognostic factor in MDS. The detection of independent cytogenetic disorders that altogether can result in CK could be used as a prognostic model for laboratory and clinical use.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"389"},"PeriodicalIF":3.6,"publicationDate":"2019-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.389","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37045058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Advances in pancreatic cancer biomarkers. 胰腺癌生物标志物研究进展

IF 3.6

Oncology Reviews Pub Date : 2019-02-01 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.410

Syed Hasan, Rojymon Jacob, Upender Manne, Ravi Paluri

引用次数: 82